首页> 外文OA文献 >Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis

【2h】

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis

机译：来自发起者的强制性非医疗切换到生物仿制物entaneRept导致医疗保健使用和成本增加吗？基于丹麦寄存器的炎症性关节炎患者的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Bente Glintborg; Rikke Ibsen; Rebecca Elisabeth Qwist Bilbo; Merete Lund Hetland; Jakob Kjellberg;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Original article: Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis [J] . Bente Glintborg, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, RMD Open . 2019,第2期

机译：原始文章：强制性的非医疗性从原始者转用仿制药依那西普是否会导致医疗保健使用和成本增加？基于丹麦注册的炎性关节炎患者研究
2. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis [J] . Glintborg B., Sorensen J., Hetland M. L. Scandinavian journal of rheumatology . 2018,第Suppla129期

机译：来自发起者的强制性非医用切换是否为生物纤维单雄兴奋剂导致门诊医疗资源的使用增加？炎症性关节炎患者的基于寄存器的研究
3. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry [J] . Glintborg Bente, Loft Anne Gitte, Omerovic Emina, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2019,第2期

机译：切换或不切换：从发起者到生物仿制物的强制性切换的全国性指南的结果。 2061例丹比奥登记处炎症关节炎患者的一年治疗结果
4. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
5. Original article: Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis [O] . Bente Glintborg, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, 2019

机译：原始文章：强制性的非医疗方式从发起者转为仿制药依那西普会导致医疗保健使用和成本增加吗？基于丹麦注册的炎性关节炎患者研究
6. FRI0103 One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study [O] . B. Glintborg, I.J. Sørensen, E. Omerovic, 2018

机译：Fri0103一年的全国性炎性关节炎患者的一年后续随从发起者转向生物仿制物的entaneAncept，专注于转回发起者的患者。一个观察丹比奥研究

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis

著录项

相似文献

相关主题

期刊订阅